Drugs / T cells
T cells
also known as
Activated T cells · ATC · Virus specific CTLs · Virus-specific Cytotoxic T-lymphocytes
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03292445 | Feb 2017 → Feb 2022 | — | Samuel Strober | Unknown | No outcome recorded |
| Phase 16 trials | ||||||
| Phase 1 | NCT05341947 | Jun 2026 → Dec 2027 | glioblastoma | Jeremy Rudnick, M.D | Withdrawn | No outcome recorded |
| Phase 1 | NCT05101213 | Jan 2023 → Jan 2027 expected | COVID-19, adenoviridae infectious disease, cancer, cytomegalovirus infection +2 | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT01946373 | Oct 2013 → Dec 2025 | melanoma | Karolinska University Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT02779439 | Jan 2013 → Dec 2017 | Epstein-Barr virus infection, adenoviridae infectious disease, cytomegalovirus infection | University of Sydney | Unknown | No outcome recorded |
| Phase 1 | NCT00837135 | Jan 2008 → Oct 2009 | malignant pancreatic neoplasm | University of Pennsylvania | Withdrawn | No outcome recorded |
| Phase 1 | NCT00586274 | Mar 2002 → Jul 2009 | Fanconi anemia | Baylor College of Medicine | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00338377 | Feb 2006 → Feb 2030 expected | melanoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-04-14 | Pfizer | REGiMMUNE Announces Collaboration with JDRF and Pfizer Inc. for Type 1 Diabetes Prevention and Treatment Promoting Regulatory T-Cells pfizer.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T cells | “At least 30 days after the stem cell infusion, patients will be dosed with T cells.” NCT00586274 ↗ |
| Known as | Activated T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05341947 ↗ |
| Known as | ATC | “Activated T cells (ATC) administered intravenously at one timepoint” NCT05341947 ↗ |
| Known as | Virus specific CTLs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02779439 ↗ |
| Known as | Virus-specific Cytotoxic T-lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05101213 ↗ |
| Modality | Cell therapy | “adoptive cell transfer” NCT00338377 ↗ |
| Route | Intravenous | “by vein infusion over 30-60 minutes” NCT00338377 ↗ |